How much funding has Exicure raised?

Exicure has raised $104.5M in total funding, most recently a Extension Round.

Who are Exicure's investors?

Exicure's investors include Luye Pharma, Bill Gates, AbbVie Ventures, Knoll Ventures, Agilent Technologies.

Where is Exicure headquartered?

Exicure is headquartered in Wilmington, Delaware, United States.

What industry is Exicure in?

Exicure operates in Biotech, Healthcare.

Exicure

Closed

Advancing Biotechnology Through Innovation and Insight

Wilmington, United States · Founded 2011 · $104.5M raised

Biotech

Healthcare

Headquarters: Wilmington, Delaware
Employees: 1–10
Founded: 2011
Business Model: B2B

Website: exicuretx.com
Total Funding: $104.5M
Last Round: $11.2M Extension RoundNov 2017
Rounds: 4

About

Exicure is a clinical-stage biotechnology company developing nucleic acid therapies using its proprietary Spherical Nucleic Acid (SNA™) technology, targeting ribonucleic acid against validated targets in neurological disorders, immuno-oncology, and inflammatory diseases. The company's lead asset is Burixafor (GPC-100), a CXCR4 antagonist in clinical trials. Exicure is headquartered in Wilmington, Delaware.

Summary

Exicure is a Biotech company based in Wilmington, United States, founded in 2011. It has raised $104.5M in total across 4 rounds, most recently a $11.2M Extension Round round in Nov 2017. Investors include Luye Pharma, Bill Gates and AbbVie Ventures.